Statins: Effects beyond cholesterol lowering

Nephrology Dialysis Transplantation

Volumn 16, Issue 9, 2001, Pages 1738-1741

  Massy, Ziad A ^a   Guijarro, Carlos ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

3 hydroxy 3 methyl glutaryl coenzyme A reductase inhibitors; Cholesterol; Statins

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; RHO FACTOR; TISSUE PLASMINOGEN ACTIVATOR;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; EPITHELIUM CELL; FIBRINOLYSIS; HUMAN; IMMUNOMODULATION; KIDNEY TUBULE EPITHELIUM; MUSCLE CELL; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

EID: 0034845366     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.9.1738     Document Type: Article

References (40)

1. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
2. Inhibition of the mevalonate pathway: Benefits beyond cholesterol reduction
3. Medical progress: Cholesterol reduction in cardiovascular disease-clinical benefits and potential mechanisms
4. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
5. Do statins prevent both cardiovascular disease and fracture
6. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
7. Statins and the risk of dementia
8. Regulation of the mevalonate pathway
9. Atherosclerosis-an inflammatory disease
10. Relationship between mevalonate pathway and arterial myocyte proliferation - In vitro studies with inhibitors of HMG-CoA reductase
11. Regulation of mesangial cell proliferation by the mevalonate pathway
12. HMG CoA reductase inhibitors - In vivo effects on carotid intimal thickening in normocholesterolemic rabbits
13. HMG-CoA reductase inhibitor suppression of glomerular cell proliferation in rats with anti-Thy-1.1 nephritis
14. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture
15. HMG-CoA reductase inhibitors induce apoptosis in mouse proximal tubular cells in primary culture
16. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to fas-ligand and cytokine-induced cell death
17. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells
18. Acute coronary syndromes: Biology
19. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia
20. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction
21. Pravastatin: An antithrombotic effect independent of the cholesterol-lowering effect
22. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis
23. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation and protects from cerebral ischemia in normocholesterolemic mice
24. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: Role of geranylgeranylation and Rho proteins
25. Long-term effects of pravastatin on plasma concentration of C-reactive protein
26. Transcription factor κB (NFκB) and renal disease
27. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: Effects of oxidation and modulation by lovastatin
28. Inhibition of proinflammatory cytokine production by pravastatin
29. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
30. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial
31. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients
32. Cracking down on caveolin: Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in modulating edothelial cell nitric oxide production
33. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals
34. Effect of pravastatin on outcomes after cardiac transplantation
35. Simvastatin reduces graft vessel disease and mortality after heart transplantation. A four-year randomized trial
36. Effect of HMG-CoA reductase inhibitors on chronic allograft rejection
37. Statins as a newly recognized type of immunomodulator
38. Pravastain increases survival and inhibits natural killer cell enhancement factor in liver transplanted rats
39. Effects of lovastatin on the immune system
40. Effects of different inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro